How it Works:
Acetyl-11-Keto-beta-Boswellic Acid, or AKBA, is one of the most potent compounds in boswellia. However, its benefits can be partially blocked by another compound found in boswellia – beta boswellic acid. Researchers have found that by removing beta boswellic acid, the effectiveness of the boswellic extract is greatly increased. Arthocin combines this unique extract with curcumin, devil’s claw, and gooseberry, three additional ingredients which help support joint mobility and health.*
A unique extract, clinically tested BosPure® boswellia helps support healthy joint function. A compound, beta boswellic acid, which interferes with its beneficial activity, has been removed, greatly increasing the effectiveness of the extract.*1,2
Curcumin from turmeric, supports multiple pathways in the body.* The clinically-tested BCM-95® curcumin in this formula has up to 10 times greater absorption that standard curcumin extracts and has shown clinical support for joint health.*3-8
Devil’s claw (Harpagophytum procumbens) is a low-growing perennial found in southern Africa. It is known by several common names, but called “devil’s claw” because of the hook-shaped “claws” on its fruit. Devil’s claw was very well-regarded among traditional practitioners in southern Africa, and was introduced into Europe by the mid-1900’s. The extract in Arthocin has been shown to increase hyaluronic acid synthesis in chondrocytes, which can improve joint lubrication, by up to 41%.*9-11
Indian gooseberry (Emblica officinalis) is also known as Amla, and has a long history of use in Ayurvedic practice. The extract in Arthocin is standardized to contain at least 35% total polyphenol content.*12,13
1. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):1100-16.
2. Poeckel D, Tausch L, Altmann A, Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid. Br J Pharmacol. 2005;146(4):514-24
3. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2):141-53.
4. Jacob A, Wu R, Zhou M, Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;89369.
5. Benny B, Antony B. Bioavailability of Biocurcumax (BCM-95). Spice India. September, 2006:11-15.
6. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax™) a novel bioenhanced preparation of curcumin. Ind J Pharm Sci. 2008:445-449.
7. Chandran B, Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Phytother Res. 2012 Mar 9. doi: 10.1002/ptr.4639.
8. Antony B, Kizhakkedath R, Benny M, Kuruvilla B. Clinical Evaluation of an Herbal Formulation in the Management of Knee Osteoarthritis. Poster presentation. Presented at the Osteoarthritis Research Symposium Internationale (OARSI) Annual World Congress on Osteoarthritis, September 15-18, 2011. San Diego, CA.
9. Harpagophytum procumbens (devil's claw). Monograph. Altern Med Rev. 2008;13(3):248-52.
10. Huang TH, Tran VH, Duke RK, et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol. 2006;104(1-2):149-55.
11. Wegener T. Therapy of degenerative diseases of the musculoskeletal system with South African devil's claw (Harpagophytum procumbens DC). Wien Med Wochenschr. 1999;149(8-10):254-7
12. Asmawi MZ, Kankaanranta H, Moilanen E, Vapaatalo H. Anti-inflammatory activities of Emblica officinalis Gaertn leaf extracts. J Pharm Pharmacol. 1993;45(6):581-4.
13. Sumantran VN, Kulkarni A, Chandwaskar R, et al. Chondroprotective potential of fruit extracts of Phyllanthus emblica in osteoarthritis. Evid Based Complement Alternat Med. 2008;5(3):329-335.